We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers Squibb (BMY) Stock Moves -0.26%: What You Should Know
Read MoreHide Full Article
Bristol-Myers Squibb (BMY - Free Report) closed the most recent trading day at $45.77, moving -0.26% from the previous trading session. This move was narrower than the S&P 500's daily loss of 0.48%. Elsewhere, the Dow lost 0.43%, while the tech-heavy Nasdaq lost 0.78%.
Coming into today, shares of the biopharmaceutical company had lost 0.56% in the past month. In that same time, the Medical sector gained 4.88%, while the S&P 500 gained 5.97%.
Investors will be hoping for strength from BMY as it approaches its next earnings release, which is expected to be July 25, 2019. In that report, analysts expect BMY to post earnings of $1.05 per share. This would mark year-over-year growth of 3.96%. Our most recent consensus estimate is calling for quarterly revenue of $5.98 billion, up 4.82% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $4.17 per share and revenue of $23.89 billion, which would represent changes of +4.77% and +5.88%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for BMY. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.24% lower. BMY is currently a Zacks Rank #4 (Sell).
Valuation is also important, so investors should note that BMY has a Forward P/E ratio of 11.01 right now. This represents a discount compared to its industry's average Forward P/E of 14.78.
Also, we should mention that BMY has a PEG ratio of 2.15. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.14 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 91, putting it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol-Myers Squibb (BMY) Stock Moves -0.26%: What You Should Know
Bristol-Myers Squibb (BMY - Free Report) closed the most recent trading day at $45.77, moving -0.26% from the previous trading session. This move was narrower than the S&P 500's daily loss of 0.48%. Elsewhere, the Dow lost 0.43%, while the tech-heavy Nasdaq lost 0.78%.
Coming into today, shares of the biopharmaceutical company had lost 0.56% in the past month. In that same time, the Medical sector gained 4.88%, while the S&P 500 gained 5.97%.
Investors will be hoping for strength from BMY as it approaches its next earnings release, which is expected to be July 25, 2019. In that report, analysts expect BMY to post earnings of $1.05 per share. This would mark year-over-year growth of 3.96%. Our most recent consensus estimate is calling for quarterly revenue of $5.98 billion, up 4.82% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $4.17 per share and revenue of $23.89 billion, which would represent changes of +4.77% and +5.88%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for BMY. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.24% lower. BMY is currently a Zacks Rank #4 (Sell).
Valuation is also important, so investors should note that BMY has a Forward P/E ratio of 11.01 right now. This represents a discount compared to its industry's average Forward P/E of 14.78.
Also, we should mention that BMY has a PEG ratio of 2.15. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.14 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 91, putting it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.